Annual CFO
-$25.12 M
-$1.66 M-7.08%
31 December 2023
Summary:
SAB Biotherapeutics annual cash flow from operations is currently -$25.12 million, with the most recent change of -$1.66 million (-7.08%) on 31 December 2023. During the last 3 years, it has fallen by -$35.12 million (-351.07%). SABS annual CFO is now -351.07% below its all-time high of $10.00 million, reached on 31 December 2020.SABS Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$6.29 M
+$1.43 M+18.47%
30 September 2024
Summary:
SAB Biotherapeutics quarterly cash flow from operations is currently -$6.29 million, with the most recent change of +$1.43 million (+18.47%) on 30 September 2024. Over the past year, it has dropped by -$1.12 million (-21.75%). SABS quarterly CFO is now -166.56% below its all-time high of $9.45 million, reached on 31 March 2021.SABS Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$38.21 M
-$1.12 M-3.03%
30 September 2024
Summary:
SAB Biotherapeutics TTM cash flow from operations is currently -$38.21 million, with the most recent change of -$1.12 million (-3.03%) on 30 September 2024. Over the past year, it has dropped by -$24.98 million (-188.84%). SABS TTM CFO is now -504.15% below its all-time high of $9.45 million, reached on 31 March 2021.SABS TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SABS Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -7.1% | -21.8% | -188.8% |
| 3 y3 years | -351.1% | -265.7% | -656.5% |
| 5 y5 years | - | - | - |
SABS Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -351.1% | at low | -265.7% | +53.2% | -656.5% | at low |
| 5 y | 5 years | -351.1% | at low | -166.6% | +53.2% | -504.1% | at low |
| alltime | all time | -351.1% | at low | -166.6% | +53.2% | -504.1% | at low |
SAB Biotherapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.29 M(-18.5%) | -$38.21 M(+3.0%) |
| June 2024 | - | -$7.72 M(-28.2%) | -$37.08 M(+8.2%) |
| Mar 2024 | - | -$10.75 M(-20.1%) | -$34.26 M(+36.4%) |
| Dec 2023 | -$25.12 M(+7.1%) | -$13.45 M(+160.2%) | -$25.12 M(+89.9%) |
| Sept 2023 | - | -$5.17 M(+5.5%) | -$13.23 M(-17.2%) |
| June 2023 | - | -$4.90 M(+205.1%) | -$15.98 M(+2.9%) |
| Mar 2023 | - | -$1.61 M(+3.3%) | -$15.53 M(-33.8%) |
| Dec 2022 | -$23.46 M | -$1.55 M(-80.4%) | -$23.46 M(-12.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$7.92 M(+78.0%) | -$26.78 M(+77.8%) |
| June 2022 | - | -$4.45 M(-53.4%) | -$15.07 M(-11.4%) |
| Mar 2022 | - | -$9.54 M(+95.5%) | -$17.00 M(-955.9%) |
| Dec 2021 | $1.99 M(-80.1%) | -$4.88 M(-228.5%) | $1.99 M(-71.1%) |
| Sept 2021 | - | $3.80 M(-159.5%) | $6.87 M(+123.8%) |
| June 2021 | - | -$6.39 M(-167.6%) | $3.07 M(-67.6%) |
| Mar 2021 | - | $9.45 M | $9.45 M |
| Dec 2020 | $10.00 M(-208.6%) | - | - |
| Dec 2019 | -$9.21 M | - | - |
FAQ
- What is SAB Biotherapeutics annual cash flow from operations?
- What is the all time high annual CFO for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual CFO year-on-year change?
- What is SAB Biotherapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly CFO year-on-year change?
- What is SAB Biotherapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for SAB Biotherapeutics?
- What is SAB Biotherapeutics TTM CFO year-on-year change?
What is SAB Biotherapeutics annual cash flow from operations?
The current annual CFO of SABS is -$25.12 M
What is the all time high annual CFO for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual cash flow from operations is $10.00 M
What is SAB Biotherapeutics annual CFO year-on-year change?
Over the past year, SABS annual cash flow from operations has changed by -$1.66 M (-7.08%)
What is SAB Biotherapeutics quarterly cash flow from operations?
The current quarterly CFO of SABS is -$6.29 M
What is the all time high quarterly CFO for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly cash flow from operations is $9.45 M
What is SAB Biotherapeutics quarterly CFO year-on-year change?
Over the past year, SABS quarterly cash flow from operations has changed by -$1.12 M (-21.75%)
What is SAB Biotherapeutics TTM cash flow from operations?
The current TTM CFO of SABS is -$38.21 M
What is the all time high TTM CFO for SAB Biotherapeutics?
SAB Biotherapeutics all-time high TTM cash flow from operations is $9.45 M
What is SAB Biotherapeutics TTM CFO year-on-year change?
Over the past year, SABS TTM cash flow from operations has changed by -$24.98 M (-188.84%)